GlycoNex Incorporation
4168
Rank in Stocks
#21187
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Share Price
$0.64017363
Last synced: 2026-11-10
Market Cap
$72.03M
Change (1 day)
0.00%
Change (1 year)
-10.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GlycoNex Incorporation (4168)
Category
Healthcare
EPS for GlycoNex Incorporation (4168)
EPS as of June 2026 TTM: $-0.08
According to GlycoNex Incorporation's latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $-0.07, a decrease compared to its 2024 EPS of $-0.06.
EPS history for GlycoNex Incorporation from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | 7.57% |
| 2025 | $-0.07 | 6.01% |
| 2024 | $-0.06 | 20.63% |
| 2023 | $-0.05 | -25.38% |
| 2022 | $-0.07 | 12.31% |
| 2021 | $-0.06 | -0.93% |
| 2020 | $-0.06 | -40.55% |
| 2019 | $-0.11 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -20,896.81% |
US
|
|
| $-7.07 | 9,289.11% |
US
|
|
| $-5.29 | 6,925.23% |
AU
|
|
| $12.88 | -17,205.05% |
BE
|
|
| $21.56 | -28,732.14% |
NL
|
Questions about GlycoNex Incorporation's earnings per share (EPS)
What is GlycoNex Incorporation's earnings per share (EPS)?
GlycoNex Incorporation's earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was GlycoNex Incorporation's earnings per share (EPS) in 2025?
In 2025, GlycoNex Incorporation's earnings per share (EPS) was $-0.07, compared with $-0.06 in 2024.
How has GlycoNex Incorporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, GlycoNex Incorporation's earnings per share (EPS) was highest in 2023 ($-0.05) and lowest in 2025 ($-0.07).
How does GlycoNex Incorporation's earnings per share (EPS) compare with similar companies?
GlycoNex Incorporation's earnings per share (EPS) ($-0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.